| Dr Ronald Kirk, OD | |
|
910 S 300 W, Blanding, UT 84511-3921 | |
| (435) 678-2324 | |
| (435) 678-3344 |
| Full Name | Dr Ronald Kirk |
|---|---|
| Gender | Male |
| Speciality | Optometry |
| Experience | 38 Years |
| Location | 910 S 300 W, Blanding, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780623595 | NPI | - | NPPES |
| 98013139 | Medicaid | UT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 112805-9934 (Utah) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Utah Navajo Health System Incorporated | 1658275649 | 39 |
News Archive
Arrayit Corporation (OTCBB: ARYC), a proprietary life sciences and nanotechnology technology leader, announces that on September 11th, 2009 Arrayit delivered its proprietary nanotechnology platform to Sandia National Laboratories in Albuquerque, New Mexico. Sandia Labs, managed by the Lockheed Martin Corporation, works with the Transportation Security Administration (TSA) and the Department of Homeland Security to enhance national security.
Researchers have shown that early dementia signs could be detected by a simple short scan of the individual's neck. The actual dementia symptoms could be seen up to 10 years after these signs are visible on the scans they add. If proven robust for all cases, this test could soon become routine for screening middle aged individuals and classifying them as high risk for dementia later in life.
The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy.
The ultimate aim is to develop an ultrasound machine that all health personnel can use without difficulty.
› Verified 2 days ago
| Provider Name | Utah Navajo Health System Incorporated |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1811991151 PECOS PAC ID: 1658275649 Enrollment ID: O20031121000239 |
News Archive
Arrayit Corporation (OTCBB: ARYC), a proprietary life sciences and nanotechnology technology leader, announces that on September 11th, 2009 Arrayit delivered its proprietary nanotechnology platform to Sandia National Laboratories in Albuquerque, New Mexico. Sandia Labs, managed by the Lockheed Martin Corporation, works with the Transportation Security Administration (TSA) and the Department of Homeland Security to enhance national security.
Researchers have shown that early dementia signs could be detected by a simple short scan of the individual's neck. The actual dementia symptoms could be seen up to 10 years after these signs are visible on the scans they add. If proven robust for all cases, this test could soon become routine for screening middle aged individuals and classifying them as high risk for dementia later in life.
The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy.
The ultimate aim is to develop an ultrasound machine that all health personnel can use without difficulty.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ronald Kirk, OD Po Box 130, Montezuma Creek, UT 84534-0130 Ph: (435) 678-2324 | Dr Ronald Kirk, OD 910 S 300 W, Blanding, UT 84511-3921 Ph: (435) 678-2324 |
News Archive
Arrayit Corporation (OTCBB: ARYC), a proprietary life sciences and nanotechnology technology leader, announces that on September 11th, 2009 Arrayit delivered its proprietary nanotechnology platform to Sandia National Laboratories in Albuquerque, New Mexico. Sandia Labs, managed by the Lockheed Martin Corporation, works with the Transportation Security Administration (TSA) and the Department of Homeland Security to enhance national security.
Researchers have shown that early dementia signs could be detected by a simple short scan of the individual's neck. The actual dementia symptoms could be seen up to 10 years after these signs are visible on the scans they add. If proven robust for all cases, this test could soon become routine for screening middle aged individuals and classifying them as high risk for dementia later in life.
The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy.
The ultimate aim is to develop an ultrasound machine that all health personnel can use without difficulty.
› Verified 2 days ago
Maverik Nicholas Shumway, Optometrist Medicare: Medicare Enrolled Practice Location: 910 S 300 W, Blanding, UT 84511 Phone: 435-678-0590 | |
Dr. Stephen Burton, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 910 S 300 W, Blanding, UT 84511 Phone: 435-678-3601 | |
Blanding Family Vision Clinic Optometrist Medicare: Not Enrolled in Medicare Practice Location: 910 S 300 W, Blanding, UT 84511 Phone: 435-678-2324 | |
Ronald D Kirk O D Inc. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 46 N Main St, Blanding, UT 84511 Phone: 435-678-2324 Fax: 435-678-3344 |